Imagine living with itchy, painful hives that just won't go away. For people with Chronic Spontaneous Urticaria (CSU), this is a daily reality, often made worse when standard treatments fail to work. CSU can disrupt daily life, making it hard to focus on anything but the discomfort. A new drug called barzolvolimab is being tested to see if it can help those who haven’t found relief with current medications. In a large study, nearly 1,000 adults will receive either barzolvolimab or a placebo (a harmless look-alike) to compare results. The goal is to see how much their symptoms improve over several months. If barzolvolimab proves effective, it could offer hope to many who feel stuck with their condition. However, it’s important to remember that this is still in the testing phase, and we need to wait for the results to understand its true impact. As researchers work towards finding better solutions, patients can remain hopeful for new options that may finally bring relief from their chronic hives.
Could a New Treatment Finally Help Those with Chronic Hives Find Relief?
Plain Language Summary
What this means for you:
A promising new treatment could soon offer hope for those struggling with chronic hives. What this means for you:
A promising new treatment could soon offer hope for those struggling with chronic hives. View Original Abstract ↓
Status: ACTIVE_NOT_RECRUITING | Phase: PHASE3
Condition(s): Chronic Spontaneous Urticaria
Intervention(s): barzolvolimab (BIOLOGICAL), Matching placebo (BIOLOGICAL)
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Detailed: This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose.
There is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period.
Approximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms.
Primary Outcome(s): Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)
Enrollment: 963 (ACTUAL)
Lead Sponsor: Celldex Therapeutics
Start: 2024-07-11 | Primary Completion: 2026-10